Skip to main content
Top
Gepubliceerd in:

11-01-2016 | Original Paper

Assessment of Cognitive Outcome Measures in Teenagers with 15q13.3 Microdeletion Syndrome

Auteurs: Emeline Crutcher, May Ali, John Harrison, Judit Sovago, Baltazar Gomez-Mancilla, Christian P. Schaaf

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 4/2016

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

15q13.3 microdeletion syndrome causes a spectrum of cognitive disorders, including intellectual disability and autism. We aimed to determine if any or all of three cognitive testing systems (the KiTAP, CogState, and Stanford–Binet) are suitable for assessment of cognitive function in affected individuals. These three tests were administered to ten individuals with 15q13.3 microdeletion syndrome (14–18 years of age), and the results were analyzed to determine feasibility of use, potential for improvement, and internal consistency. It was determined that the KiTAP, CogState, and Stanford–Binet are valid tests of cognitive function in 15q13.3 microdeletion patients. Therefore, these tests may be considered for use as objective outcome measures in future clinical trials, assessing change in cognitive function over a period of pharmacological treatment.
Literatuur
go back to reference Aman, M. G., Novotny, S., Samango-Sprouse, C., Lecavalier, L., Leonard, E., Gadow, K. D., et al. (2004). Outcome measures for clinical drug trials in autism. CNS Spectrums, 9(1), 36–47.PubMedPubMedCentral Aman, M. G., Novotny, S., Samango-Sprouse, C., Lecavalier, L., Leonard, E., Gadow, K. D., et al. (2004). Outcome measures for clinical drug trials in autism. CNS Spectrums, 9(1), 36–47.PubMedPubMedCentral
go back to reference Freedman, R. (2014). α7-nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia. Annual Review of Medicine, 65(September 2013), 245–261.CrossRefPubMed Freedman, R. (2014). α7-nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia. Annual Review of Medicine, 65(September 2013), 245–261.CrossRefPubMed
go back to reference Grondhuis, S., & Mulick, J. (2013). Comparison of the Leiter International Performance Scale-Revised and the Stanford–Binet Intelligence Scales, 5th Edition, in children with autism spectrum disorders. American Journal on Intellectual and Developmental Disabilities, 118(1), 44–54.CrossRefPubMed Grondhuis, S., & Mulick, J. (2013). Comparison of the Leiter International Performance Scale-Revised and the Stanford–Binet Intelligence Scales, 5th Edition, in children with autism spectrum disorders. American Journal on Intellectual and Developmental Disabilities, 118(1), 44–54.CrossRefPubMed
go back to reference Hellwig-Brida, S., Daseking, M., Keller, F., Petermann, F., & Goldbeck, L. (2011). Effects of methylphenidate on intelligence and attention components in boys with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 21(3), 245–253.CrossRefPubMed Hellwig-Brida, S., Daseking, M., Keller, F., Petermann, F., & Goldbeck, L. (2011). Effects of methylphenidate on intelligence and attention components in boys with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 21(3), 245–253.CrossRefPubMed
go back to reference Jucaite, A., Öhd, J., Potter, A. S., Jaeger, J., Karlsson, P., Hannesdottir, K., et al. (2014). A randomized, double-blind, placebo-controlled crossover study of α4β2* nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorder. Psychopharmacology, 231(6), 1251–1265.CrossRefPubMedPubMedCentral Jucaite, A., Öhd, J., Potter, A. S., Jaeger, J., Karlsson, P., Hannesdottir, K., et al. (2014). A randomized, double-blind, placebo-controlled crossover study of α4β2* nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorder. Psychopharmacology, 231(6), 1251–1265.CrossRefPubMedPubMedCentral
go back to reference Kaufmann, L., Zieren, N., Zotter, S., Karall, D., Scholl-Bürgi, S., Haberlandt, E., et al. (2010). Predictive validity of attentional functions in differentiating children with and without ADHD: A componential analysis. Developmental Medicine and Child Neurology, 52(4), 371–378.CrossRefPubMed Kaufmann, L., Zieren, N., Zotter, S., Karall, D., Scholl-Bürgi, S., Haberlandt, E., et al. (2010). Predictive validity of attentional functions in differentiating children with and without ADHD: A componential analysis. Developmental Medicine and Child Neurology, 52(4), 371–378.CrossRefPubMed
go back to reference Knox, A., Schneider, A., Abucayan, F., Hervey, C., Tran, C., Hessl, D., et al. (2012). Feasibility, reliability, and clinical validity of the Test of Attentional Performance for Children (KiTAP) in Fragile X syndrome (FXS). Journal of Neurodevelopmental Disorders, 4(1), 2. doi:10.1186/1866-1955-4-2.CrossRefPubMedPubMedCentral Knox, A., Schneider, A., Abucayan, F., Hervey, C., Tran, C., Hessl, D., et al. (2012). Feasibility, reliability, and clinical validity of the Test of Attentional Performance for Children (KiTAP) in Fragile X syndrome (FXS). Journal of Neurodevelopmental Disorders, 4(1), 2. doi:10.​1186/​1866-1955-4-2.CrossRefPubMedPubMedCentral
go back to reference Lowther, C., Costain, G., Stavropoulos, D. J., Melvin, R., Silversides, C. K., Andrade, D. M., et al. (2014). Delineating the 15q13.3 microdeletion phenotype: A case series and comprehensive review of the literature. Genetics in Medicine, 17(2), 149–157.CrossRefPubMedPubMedCentral Lowther, C., Costain, G., Stavropoulos, D. J., Melvin, R., Silversides, C. K., Andrade, D. M., et al. (2014). Delineating the 15q13.3 microdeletion phenotype: A case series and comprehensive review of the literature. Genetics in Medicine, 17(2), 149–157.CrossRefPubMedPubMedCentral
go back to reference Mollica, C. M., Maruff, P., & Vance, A. (2004). Development of a statistical approach to classifying treatment response in individual children with ADHD. Human Psychopharmacology, 19(7), 445–456.CrossRefPubMed Mollica, C. M., Maruff, P., & Vance, A. (2004). Development of a statistical approach to classifying treatment response in individual children with ADHD. Human Psychopharmacology, 19(7), 445–456.CrossRefPubMed
go back to reference Ozonoff, S., Goodlin-Jones, B. L., & Solomon, M. (2005). Evidence-based assessment of autism spectrum disorders in children and adolescents. Journal of Clinical Child and Adolescent Psychology, 34(3), 523–540.CrossRefPubMed Ozonoff, S., Goodlin-Jones, B. L., & Solomon, M. (2005). Evidence-based assessment of autism spectrum disorders in children and adolescents. Journal of Clinical Child and Adolescent Psychology, 34(3), 523–540.CrossRefPubMed
go back to reference Rothmann, K., Hillmer, J., & Hosser, D. (2014). Evaluation of the Musical Concentration Training with Pepe (MusiKo mit Pepe) for children with attention deficits. Zeitschrift für Kinder-und Jugendpsychiatrie und Psychotherapie, 42(5), 325–335.CrossRefPubMed Rothmann, K., Hillmer, J., & Hosser, D. (2014). Evaluation of the Musical Concentration Training with Pepe (MusiKo mit Pepe) for children with attention deficits. Zeitschrift für Kinder-und Jugendpsychiatrie und Psychotherapie, 42(5), 325–335.CrossRefPubMed
go back to reference Sandler, A. (2005). Placebo effects in developmental disabilities: Implications for research and practice. Mental Retardation and Developmental Disabilities Research Reviews, 11(2), 164–170.CrossRefPubMed Sandler, A. (2005). Placebo effects in developmental disabilities: Implications for research and practice. Mental Retardation and Developmental Disabilities Research Reviews, 11(2), 164–170.CrossRefPubMed
go back to reference Schaaf, C. P. (2014). Nicotinic acetylcholine receptors in human genetic disease. Genetics in Medicine, 16(9), 649–656.CrossRefPubMed Schaaf, C. P. (2014). Nicotinic acetylcholine receptors in human genetic disease. Genetics in Medicine, 16(9), 649–656.CrossRefPubMed
go back to reference Silverman, W., Miezejeski, C., Ryan, R., Zigman, W., Krinsky-McHale, S., & Urv, T. (2010). Stanford–Binet and WAIS IQ differences and their implications for adults with intellectual disability (aka mental retardation). Intelligence, 38(2), 242–248.CrossRefPubMedPubMedCentral Silverman, W., Miezejeski, C., Ryan, R., Zigman, W., Krinsky-McHale, S., & Urv, T. (2010). Stanford–Binet and WAIS IQ differences and their implications for adults with intellectual disability (aka mental retardation). Intelligence, 38(2), 242–248.CrossRefPubMedPubMedCentral
go back to reference Tropeano, M., Andrieux, J., Vassos, E., & Collier, D. A. (2014). Clinical utility gene card for: 15q13.3 microdeletion syndrome. European Journal of Human Genetics, 22(11), 1338.CrossRefPubMedCentral Tropeano, M., Andrieux, J., Vassos, E., & Collier, D. A. (2014). Clinical utility gene card for: 15q13.3 microdeletion syndrome. European Journal of Human Genetics, 22(11), 1338.CrossRefPubMedCentral
go back to reference Yamashita, Y., Mukasa, A., Anai, C., Honda, Y., Kunisaki, C., Koutaki, J., et al. (2011). Summer treatment program for children with attention deficit hyperactivity disorder: Japanese experience in 5 years. Brain and Development, 33(3), 260–267.CrossRefPubMed Yamashita, Y., Mukasa, A., Anai, C., Honda, Y., Kunisaki, C., Koutaki, J., et al. (2011). Summer treatment program for children with attention deficit hyperactivity disorder: Japanese experience in 5 years. Brain and Development, 33(3), 260–267.CrossRefPubMed
Metagegevens
Titel
Assessment of Cognitive Outcome Measures in Teenagers with 15q13.3 Microdeletion Syndrome
Auteurs
Emeline Crutcher
May Ali
John Harrison
Judit Sovago
Baltazar Gomez-Mancilla
Christian P. Schaaf
Publicatiedatum
11-01-2016
Uitgeverij
Springer US
Gepubliceerd in
Journal of Autism and Developmental Disorders / Uitgave 4/2016
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI
https://doi.org/10.1007/s10803-015-2694-0